Abstract
The worldwide utilization of (68) Ga-radionuclide for the fundamental research and clinical applications is growing exponentially. A broad range of (68) Ga-based imaging agents has been explored during recent years. The development of new clinically useful agents is encouraged by many factors; for example, increasing role of positron emission tomography (PET) in nuclear medicine, discovery of new biomarkers, accessibility of (68) Ga, and establishment of PET radiopharmaceutical regulation and legislation. The focus of this review resides on the reports regarding (68) Ga-related research and applications published during 2013 to June 2014.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Labelled Compounds and Radiopharmaceuticals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.